PharmaBlock commissions Zhejiang peptide plant
Analysis based on 6 articles · First reported Jun 04, 2026 · Last updated Jun 04, 2026
The commissioning of PharmaBlock Sciences' new peptide pilot-scale GMP plant is expected to positively impact the company's stock price due to expanded manufacturing capabilities and strategic growth in new molecular modalities. This development could also signal increased competition or innovation within the pharmaceutical and biotechnology sectors, potentially affecting other players in the industry.
PharmaBlock Sciences announced the commissioning of its first peptide pilot-scale GMP plant at its China — Zhejiang manufacturing site on June 4, 2026. This new facility is designed to support client programs transitioning from early-stage R&D to pilot-scale GMP production, offering end-to-end capabilities including synthesis, cleavage, purification, and lyophilization. The plant features a core synthesis platform with 600 L reactor volume, integrated cleavage systems, high-speed centrifuges, large-scale drying ovens, classified clean areas (Grade D and Class C), advanced preparative chromatography, and an intelligent sterile lyophilization platform. Dr. Minmin Yang, Chairman of PharmaBlock Group, highlighted this as a major milestone in PharmaBlock Sciences' strategic expansion into new molecular modalities like oligonucleotides, peptides, and complex conjugates, building on its expertise in building block design and green chemistry principles.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard